Arch Biopartners ARCH.V · CAD

Market value

C$61.7m

Last close × shares

Volume

6.1k

Shares, 9 Nov 2026

Its shares trade on TSX Venture under the ticker ARCH.V. It has been listed since 9 October 1996. In the fiscal year to 30 September 2023, it reported revenue of C$2.0m and a net loss of C$3.3m. At that date it held total assets of C$1.2m and shareholders' equity of −C$5.5m.

Arch Biopartners, Inc. is a biotechnology company, which focuses on the development of technologies that have the potential to make a significant medical or commercial impact. The company is headquartered in Toronto, Ontario. The firm is focused on the clinical development of its drug platform in targeting dipeptidase-1 (DPEP-1) mediated organ inflammation in the lungs, liver and kidneys. Its lead drug candidate is LSALT Peptide (Metablok). LSALT Peptide is developed for targeting organ inflammation often experienced in hospitalized COVID-19 patients. The company focuses on therapeutic development of LSALT Peptide and other DPEP-1 targeting drug candidates for new indications where inflammation of the lungs, liver and kidneys is an unmet problem. The company has additional technology platforms in its portfolio including AB569, which focuses on preventing antibiotic resistant bacterial infections; Borg, which is a peptide-solid surface interface, and MetaMx, which is a synthetic molecule that target brain tumor initiating cells and invasive glioma cells.

Figures and description from our data supplier, not checked against the company's own report.

More about Arch Biopartners →

We have not reported on Arch Biopartners yet.

Due on 28 Jan 2027. Analysts expect earnings of -0.01 a share.

Leaves out fees, taxes and financing.

Chart

TradingView

Close and company data

Our data supplier

News

Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.